Literature DB >> 27523635

Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Ju Dong Yang1, Manal F Abdelmalek2, Cynthia D Guy3, Ryan M Gill4, Joel E Lavine5, Katherine Yates6, Jagpal Klair7, Norah A Terrault8, Jeanne M Clark9, Aynur Unalp-Arida10, Anna Mae Diehl2, Ayako Suzuki11.   

Abstract

BACKGROUND & AIMS: Sex and sex hormones can affect responses of patients with nonalcoholic fatty liver disease (NAFLD) to metabolic stress and development of hepatocyte injury and inflammation.
METHODS: We collected data from 3 large U.S. studies of patients with NAFLD (between October 2004 and June 2013) to assess the association between histologic severity and sex, menopause status, synthetic hormone use, and menstrual abnormalities in 1112 patients with a histologic diagnosis of NAFLD. We performed logistic or ordinal logistic regression models, adjusting for covariates relevant to an increase of hepatic metabolic stress.
RESULTS: Premenopausal women were at an increased risk of lobular inflammation, hepatocyte ballooning, and Mallory-Denk bodies than men and also at an increased risk of lobular inflammation and Mallory-Denk bodies than postmenopausal women (P < .01). Use of oral contraceptives was associated with an increased risk of lobular inflammation and Mallory-Denk bodies in premenopausal women, whereas hormone replacement therapy was associated with an increased risk of lobular inflammation in postmenopausal women (P < .05).
CONCLUSIONS: Being a premenopausal woman or a female user of synthetic hormones is associated with increased histologic severity of hepatocyte injury and inflammation among patients with NAFLD at given levels of hepatic metabolic stress.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibrosis; Gender Differences; Risk Factor Analysis

Mesh:

Substances:

Year:  2016        PMID: 27523635      PMCID: PMC5161542          DOI: 10.1016/j.cgh.2016.07.034

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  15 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Nonalcoholic steatohepatitis clinical research network.

Authors: 
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

3.  Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.

Authors:  Ayako Suzuki; Manal F Abdelmalek; Aynur Unalp-Arida; Katherine Yates; Arun Sanyal; Cynthia Guy; Anna Mae Diehl
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-20       Impact factor: 11.382

4.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Authors:  Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2008-09-10       Impact factor: 2.226

6.  Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.

Authors:  Ju Dong Yang; Manal F Abdelmalek; Herbert Pang; Cynthia D Guy; Alastair D Smith; Anna Mae Diehl; Ayako Suzuki
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

7.  Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Authors:  Cynthia D Guy; Ayako Suzuki; Marzena Zdanowicz; Manal F Abdelmalek; James Burchette; Aynur Unalp; Anna Mae Diehl
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

8.  Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults.

Authors:  Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

9.  Increased production of sonic hedgehog by ballooned hepatocytes.

Authors:  Fatima Rangwala; Cynthia D Guy; Jiuyi Lu; Ayako Suzuki; James L Burchette; Manal F Abdelmalek; Wei Chen; Anna Mae Diehl
Journal:  J Pathol       Date:  2011-05-05       Impact factor: 7.996

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  22 in total

1.  Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

Authors:  Austin Morrell; Brian P Tripet; Brian J Eilers; Megan Tegman; Damon Thompson; Valérie Copié; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2019-12-16       Impact factor: 6.048

Review 2.  Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Stefano Ballestri; DeLisa Fairweather; Sanda Win; Tin A Than; Manal F Abdelmalek; Ayako Suzuki
Journal:  Hepatology       Date:  2019-09-23       Impact factor: 17.425

3.  Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.

Authors:  Jung Il Lee; Jung-Hwan Yu; Sung Gwe Anh; Hyun Woong Lee; Joon Jeong; Kwan Sik Lee
Journal:  Oncologist       Date:  2019-01-24

Review 4.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Stavroula A Paschou; Stergios A Polyzos; Panagiotis Anagnostis; Dimitrios G Goulis; Christina Kanaka-Gantenbein; Irene Lambrinoudaki; Neoklis A Georgopoulos; Andromachi Vryonidou
Journal:  Endocrine       Date:  2019-09-19       Impact factor: 3.633

Review 5.  Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Irene Lambrinoudaki; Dimitrios G Goulis
Journal:  Hormones (Athens)       Date:  2022-05-09       Impact factor: 3.419

Review 6.  Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine.

Authors:  Livianna Carrieri; Alberto Ruben Osella; Fausto Ciccacci; Gianluigi Giannelli; Maria Principia Scavo
Journal:  Biomedicines       Date:  2022-05-20

Review 7.  The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones.

Authors:  Linlin Xu; Yuan Yuan; Zhaodi Che; Xiaozhi Tan; Bin Wu; Cunchuan Wang; Chengfang Xu; Jia Xiao
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

8.  Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.

Authors:  Monika Sarkar; Jennifer L Dodge; Ruth M Greenblatt; Mark H Kuniholm; Jack DeHovitz; Michael Plankey; Andrea Kovacs; Audrey L French; Eric C Seaberg; Igho Ofotokun; Margaret Fischl; Edgar Overton; Erin Kelly; Peter Bacchetti; Marion G Peters
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

9.  Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Noel T Mueller; Tiange Liu; Elana B Mitchel; Katherine P Yates; Ayako Suzuki; Cynthia Behling; Joel E Lavine
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

10.  A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease.

Authors:  Sakil Kulkarni; Nadia Naz; Hongjie Gu; Janis M Stoll; Michael D Thompson; Brian J DeBosch
Journal:  Clin Obes       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.